Category: Histogenics Corp.
AngioDynamics names Joseph DeVivo as its new CEO, replacing Jan Keltjens, and reveals the departure of one of its senior business development executives.
AngioDynamics Inc. (NSDQ:ANGO) named a replacement for former CEO Jan Keltjens, who left suddenly in June, tapping Joseph DeVivo for the corner office.
The Latham, N.Y.-based oncology device company also revealed the resignation of senior vice president of business development Lynda Wallace, according to SEC filings.
Histogenics CEO Patrick O'Donnell tells MassDevice.com that the regenerative medicine company plans to use the $49 million it just raised to fund a Phase III trial of its NeoCart regenerative knee cartilage treatment.
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
Histogenics raises $49 million to fund a Phase III trial of its NeoCart regenerative knee cartilage treatment and get CE Mark approval for its VeriCart knee treatment in the European Union.
Histogenics said it raised another $49 million for its regenerative cartilage treatments, as it proceeds with a clinical trial for its NeoCart treatment and pursues CE Mark approval for its VeriCart system.
The round was led by Sofinnova Ventures and including backing from new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund. Prior backers ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also kicked in.
Dr. Nalini Rajamannan, who sparked a federal investigation into fellow physician and inventor of the Myxo annuloplasty ring for allegedly implanting the device in patients without consent, is fired from Northwestern University after being denied tenure.
A Northwestern University cardiologist who sparked a federal investigation into a fellow physician for alleged misconduct was fired after being denied tenure.
Dr. Nalini Rajamannan, who was an associate professor of medicine at the university, believes she was fired for providing evidence to federal investigators and for challenging the university's star surgeon.
Source:
Business Wire Health: Clinical Trials News
WALTHAM, Mass.--(BUSINESS WIRE)--Regenerative medicine company Histogenics Corporation appoints Michael Lewis, M.D. to CMO and Peter Hamilton to VP of Manufacturing & Production to support Phase 3 development of NeoCart.
Patrick O'Donnell, CEO of regenerative knee implant developer Histogenics, denies an Israeli news outlet's report that the company plans "substantial" layoffs in its R&D operation there following its merger with Prochon Biotech.
Histogenics Corp., fresh from a merger with fellow Bay State firm Prochon Biotech, has no plans for layoffs, contrary to a report in an Israeli journal.
The Globes new outlet, a business daily based in Rishon Le-Zion, Israel, reported yesterday that Histogenics "will make substantial cuts" to its R&D unit in Ness Ziona.
Histogenics, which merged with ProChon Biotech last week, reels in $34 million in equity and debt funding as part of the deal.
Histogenics Corp. brought in more than $34 million in equity and debt financing after its acquisition of fellow Bay State firm ProChon Biotech Ltd.
The two companies merged in an all-stock deal that brings ProChon CEO Patrick O'Donnell into the Histogenics corner office.
O'Donnell told MassDevice.com last week that a deal has been in the works since the early part of 2011.
